Nexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXperts
You are unauthorized to view this page. Username Password Remember Me Forgot Password
Immunology
Nexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXperts
Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of assay development and advanced laboratory testing is pleased to announce the signing of a definitive agreement, subject to conditions precedent, to acquire ImmunXperts. The closing of the transaction is expected by the end of March. Based in the Brussels South Charleroi Biopark